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Dowgression for about a year. Although the outcomes in earlier disease states may include changes in bio-
markers, the clinical effectiveness of any intervention can ultimately only be assessed by a patient’s
self-reported well-being. A better understanding of earlier manifestations of Alzheimer’s disease and
the drive for relevant outcome measures, allied to technological advances in artificial intelligence,
have mediated the electronic Person-Specific Outcome Measure (ePSOM) development program.
Methods: There are 4 sequential stages in the ePSOM development program—(1) literature review,
(2) focus group study, (3) national survey, and (4) development of an app for capturing person-specific
outcomes. Here, we report the overall approach to the program incorporating our literature review on
patient-reported outcome measures and patient preferences in the Alzheimer’s disease population.
Results: Alzheimer’s disease trials do not use any patient-reported outcomemeasures. Quality of life
measures are often used as proxies for this, but they do not capture individual needs. Therefore, trials
currently fail to reflect the participant’s aspirations for effect but rather default to clinicostatistical
measure of cognition and function. There is no implementation of patient preferences despite evi-
dence that understanding preferences may influence adherence to treatment.
Discussion: It is important to consider preferences for an intervention and use PROMs for the mea-
sure of effectiveness given that both risk and benefit are judged by the recipient of the treatment. The
ePSOM development program will deliver the methodology for incorporating meaningful outcomes
in clinical trials to expand upon current biological and clinical measurements of effectiveness.
 2018 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Keywords: Patient preferences; Patient-reported outcome measures; Alzheimer’s disease clinical trials; Dementia; Clinicaleffectiveness1. Introduction
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used to treat the symptoms of Alzheimer’s disease (AD) with
cholinesterase inhibition remaining the predominant target
in AD pharmacology [2,3]. Current pharmacological
interventions for AD delay clinical symptom progression
in people with a dementia syndrome for no longer than
about a year, mediating a significant and ongoing drive
toward finding effective pharmacological interventions thatimer’s Association. This is an open access article under the CC BY-NC-ND
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significantly. To date, a drug’s measure of effect has been
based on cognition and function.
It is known from other fields of medicine that in devel-
oping new interventions and offering treatment options to
patients, patient preferences toward the treatment being
tested impact on treatment compliance and ultimately
longer-term positive outcomes [4–7]. Throughout this
article, we refer to patient preferences as the thought
processes patients or trial participants undertake when
making health care decisions—the risk versus benefit
analysis focuses on the personal expectations for desired
benefits and the risks individuals are willing to take to
achieve these benefits.
Outcome measures in clinical trials should reflect treat-
ment preferences to assess whether an intervention offers a
real benefit to patients while keeping potential risks at a level
that trial participants would tolerate. The “real benefit to
patients” should ultimately and ideally be set by the pa-
tients themselves using patient-reported outcome measures
(PROMs). It is noteworthy that risks versus benefit evalua-
tions are currently determined on behalf of patients by third
parties, for example, study sponsors, investigators, ethics
committees, payers, or regulators without systematically
taking into account the individual’s perspectives or being
able to refer to data in the trial to inform these evaluations.
Even if some patient input is included on committee levels,
patient advisors are not reflective of the patient populationAssumption for drug efficacy 
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participant in clinical trials (who will be the future target
population for the intervention) need not continue ad infini-
tum if a solution was found to effectively and accurately
measure the participants’ choice of outcomes and how these
balance against how much risk they are willing to accept to
achieve these.
As interventions move earlier in the disease course (e.g.,
via programs like the European Prevention of Alzheimer’s
Dementia) [8], disease-modifying trials now employ more
sensitive cognitive and functional outcomes that are ex-
pected to correlate more closely with relevant early biolog-
ical changes [9] and may also be more closely correlated
to a participant’s ability to maintain important patient-
reported outcomes or even recovery of these. The miscon-
ception that cognitive or functional outcomes cannot be
measured at such an early disease stage to reflect treatment
success has led to a tendency to seek surrogate biomarker
outcomes. As shown in Fig. 1, the traditional understanding
has been that biomarker changes precede changes in cogni-
tion and function, which in turn precede changes in
PROMs. One example of a PROM is a tool we are devel-
oping—an electronic Person-Specific Outcome Measure
(ePSOM), which would allow us to look at correlations
in specific elements of a PROM and link it with a specific
biomarker. Fig. 1 highlights that different outcomes are
best applied at different stages of illness. While in oncology
and other disease areas there is a close correlation betweenfunction
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measured using, e.g., biopsy), then this is lacking in AD.
We note that currently used biomarker outcomes are “two
steps” away from PROMs. In Fig. 1, we illustrate the two
steps by which biomarker outcomes are away from PROMs
outcomes in terms of surrogacy. An ideal surrogate
outcome gives confidence that a change in the biomarker
will be associated with high likelihood of a later change
in the main outcome of interest. If we consider PROMs
as the ideal outcomes of interest, then currently biomarker
change will give little assurance of a later change in well-
being of the patient. Given that outcomes are so loosely
tied to each other, it is impractical for a patient to base a
preference decision on such indistinct outcomes such as
biomarkers and cognition. Using outcomes in AD trials
that reflect the biological and cognitive consequences of
disease may gain in objectivity but lose out in terms of rele-
vance to the person participating in the trial; and although
using PROMs in preclinical or prodromal disease may
seem challenging, it is in this very population where there
is a clear and immediate need to understand the patient’s
perspective and the risks they would be prepared to take
to delay dementia onset especially when the interventions
being currently trialled may have more safety issues than
existing treatments.
It is highlighted in the recent United States Food
and Drug Administration (FDA) guidelines that as AD
drug trials move to an earlier phase in the disease, we
must now develop optimal measures to assess treatment
benefit [10,11] as well as necessarily incorporate patient
preferences in the process [12]. So far, however, technical
and statistical limitations have hampered the use of PROMs
in clinical trials. It is critical therefore that purposeful, large
scale research is undertaken to identify person-specific
outcome priorities, understand patient preferences, and
develop a system for capturing these that can be incorpo-
rated routinely in clinical trials with the necessary validity
for regulatory acceptance.1.1. Measuring meaningful benefits in AD clinical trials
PROMs reflect an individual’s views on what they define
as an effective treatment and, importantly, capture benefits
specific and meaningful to that particular person. Other
fields of medicine already incorporate PROMs developed
specifically for the target population, for example, oncology
(see [13,14]). However, a recent review looking at outcome
measures used in disease-modifying trials in AD [15]
concluded that current AD clinical trials do not use PROMs
and rely solely on other domains to measure drug efficacy.
There may be several reasons for this. Some research studies
accept activities of daily living and quality of life (QoL)
measures as a proxy for PROMs. In our view, QoL measures
are too generic and not specific to a person as well as often
incorporate a carer perspective rather than relying on the per-
son. We also note that QoL measures are developed throughDownloaded for Anonymous User (n/a) at NESLI The University of Ed
For personal use only. No other uses without permission. Cpopulation-level research and therefore lose the specificity
to an individual. Furthermore, relevant to our objective,
QoL measures are predominantly used in the Alzheimer’s
dementia populations so would not be appropriate for use
in the prodromal stages of AD. The use of other proxy mea-
sures of PROMs (e.g., cognition) may reflect a propensity or
tradition for measuring effectiveness from a clinical as
opposed to a patient perspective. Finally, health-related out-
comes measures or health utility indexes are often used as
proxies for patient preference measures, although the valid-
ity of these measures to accurately report patient views on
benefit versus risk analysis and experience in treatment effi-
cacy is uncertain (e.g., [16]). One can therefore see that there
is a pressing need to apply scientific rigor and purpose to find
a means to measure PROMs in people across the AD spec-
trum and to use these outcomes to link with treatment pref-
erences.
In 2007, the International Psychogeriatric Association
produced a consensus statement on defining and measuring
treatment benefits in dementia trials [17]. The statement
concludes that outcomes can include effects on people
with dementia regarding cognition, behavioral and psycho-
logical symptoms, QoL, global assessments, and activities
of daily living and that these measures should account for
the cultural context and education of the population.
PROMs were not mentioned in this statement produced
over 10 years ago. However, given recent developments
and regulatory shifts, we consider that effectiveness of an
intervention should be defined by maintenance of well-
being. In AD, this concept could be defined specifically
by the patient as a PROM. We are not alone in this view.
A recent review notes that newly developed treatments
across the AD spectrum for approval by the FDA should
provide evidence that the treatment translates into “mean-
ingful benefits for the treatment group” [18]—a position
supported by the EMA [19].
Although empirical evidence of patient preference in AD
with a real-world clinical trial population is very limited,
the value of this information may be substantial regarding
decisions on drug development and later marketing. A study
of healthy older Americans’ perception of AD explored
preferences were they to undergo hypothetical AD treat-
ment, showing that participants were willing to accept
serious adverse-event risks in return for effective disease-
modifying benefits of new drugs [20]. A recent meta-
analysis summarizing evidence from 33 cohort surveys
about the general public’s attitude toward AD found that
belief in the value of seeking treatment was high [21]. How-
ever, despite these positive attitudes to intervention in the
general public, reviews involving a clinical population
who are already symptomatic have found that adherence
to AD medication is low [22], which may reflect a lack of
clear understanding of preferences in the originating clin-
ical trials and lack of relevance of clinical outcome mea-
sures to reflect the patient’s perspective. In essence, a lack
of understanding of the clinical trial about the researchinburgh from ClinicalKey.com by Elsevier on January 08, 2019.
opyright ©2019. Elsevier Inc. All rights reserved.
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and how they may meaningfully benefit from it could
mediate low adherence after the drug is launched.
Given (1) the requirements now being established for
clinical trials in AD, (2) the desire to improve long-term
adherence and compliance with new medications, and (3)
technology advancements in artificial intelligence creating
opportunities for the assessment of PROMs, we established
the ePSOMs program.1.2. The aim of the ePSOM development program
In this article, we present the background underpinning
the ePSOM development program. There are four sequen-
tial stages in the program: (1) literature review, (2) focus
groups to elicit what matters to people when developing
new treatments for AD [23], (3) design and launch of a na-
tional survey, and (4) incorporation of all knowledge gained
in steps (1–3) to ultimately lead to the development of an
app for capturing longitudinally person-specific outcomes
and preferences.
The objective of the ePSOM development program is to
deliver a valid and reliable technical solution that has regu-
latory compliance for use in clinical trials in people with
AD, optimized for people with preclinical or prodromal
Alzheimer’s dementia. An interactive dialog system [24]
for gathering patient feedback is envisaged, which will be
deployed as an app on networked mobile devices (smart-
phones, tablets) and conventionalWeb browsers. This dialog
system will include methods for data gathering through
different input modalities, including typing, touch screen,
and speech interaction. Speech interaction allows the soft-
ware to capture not only what patients said but also how
they said it. Once these data have been collected, statistical
learning methods will be employed to extract outcome pref-
erences information, as well as analyze the patient’s voice
for cues related to these preferences. Although usability
and implementation aspects need special attention in the
deployment of these technologies [25], it has been acknowl-
edged, in other fields of medicine, that electronic methods
for collection of PROMs have the potential to minimize
costs and improve the effectiveness of capturing patient
feedback [25,26].2. Stage 1: Literature review
2.1. Methodology
As the first step in the program, we conducted a thorough
literature review on PROMs and patient preferences as they
were used in clinical trials or other research settings in the
AD population. We specified AD because that is the context
where our ePSOM will be implemented. As much of this
literature dates back over the last 20 years, the term mild
cognitive impairment (MCI) is used to describe the prodro-
mal stage in the AD population.Downloaded for Anonymous User (n/a) at NESLI The University of Ed
For personal use only. No other uses without permission. CThe first search was to identify papers referring to
PROMs in the AD and MCI population in clinical trials
(see Appendix 1); the second search was to identify papers
referring to patient preferences in the AD and MCI popula-
tion (see Appendix 2). EMBASE database was searched
from 1980 until 06 August 2018 using OVID SP. Reference
lists of included papers and review articles were also
checked, and an additional search was done on Google
Scholar. Articles published in English were included.
2.1.1. Search I—PROMs
2.1.1.1. Inclusion criteria
 Primary research paper
 Included participants with MCI or subjective cognitive
impairment or Alzheimer’s disease—OR healthy
volunteers hypothesizing about MCI or Alzheimer’s
disease
 Used a PROM or goal-setting measure
2.1.1.2. Exclusion criteria
 Study population without neurocognitive disorders
 No PROM or goal-setting measures used2.1.2. Search II—preferences
2.1.2.1. Inclusion criteria
 Primary research papers
 Include participants with MCI or subjective cognitive
impairment or mild Alzheimer’s disease—OR healthy
volunteers hypothesizing about MCI or Alzheimer’s
disease
Refer to patient preferences in the context of health care
decisions.
2.1.2.2. Exclusion criteria
 Study population without neurocognitive disorders
 No explicit patient preferences (e.g., only comparison
between patient and caregiver ratings in various scales)3. Results
3.1. Search I—PROMS
The search yielded 41 results. The titles and abstracts of
the 41 papers were reviewed against the inclusion/exclusion
criteria, which left three papers. The majority of papers
excluded were either review papers, opinion pieces, or
were not relevant to the AD population, for example,
focusing on HIV or a rehabilitation setting. Additional
search strategy was then adopted by reviewing the reference
lists of the remaining papers—this resulted in 2 new papers
though they both used a PROM, which was already repre-
sented in the main search result. After a review of full textsinburgh from ClinicalKey.com by Elsevier on January 08, 2019.
opyright ©2019. Elsevier Inc. All rights reserved.
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PROMs were included in the review.
Therefore, a total of three different PROMs used in the
Alzheimer’s disease or MCI population were identified
([27–30] Appendix 3: PROMs literature review summary).
None of these have been approved by regulatory bodies as
a PROM in AD trials. A recent review and consensus state-
ment we identified [15] looked at outcome measures
currently used in AD trials up to 2016 and concurred with
our observations. Their search yielded 125 previous and
ongoing trials with 81 different outcome measures broadly
fitting into six domains. However, the review did not identify
any PROMs currently used in clinical trials. These findings
were corroborated by another review looking at dementia
studies [31] where no PROMs were identified.3.2. Search II—preferences
The search yielded 625 results. The titles and abstracts
of the 625 papers were reviewed against the inclusion/
exclusion criteria, which left 31 papers. The majority of pa-
pers excluded were not relevant to the AD population
focusing on health care decisions generally or had no pri-
mary data. Reviewing the reference lists of the 31 papers
yielded three new papers. After a review of full texts was
carried out, 15 papers referring to patient preferences in
the Alzheimer’s disease or MCI population were included
([32–46] Appendix 4: Preferences literature review sum-
mary).
In the literature search for patient preferences in the AD
population, the 15 papers we identified were both quantita-
tive and qualitative in study design, using a variety of
methods for eliciting patient preferences. All the papers
identified explored patient preferences in a hypothetical sce-
nario, and none of the papers used patient preferences in
conjunction with enrolling or enrolled participants in a clin-
ical trial.3.3. Summary of literature review
The reviews conducted highlighted the paucity of evi-
dence relating to the direct use of PROMs or preferences
in clinical trials in AD. Three measures of PROMs have
been developed which, on the basis of the importance af-
forded to these measures by regulators and others, reflects
a very small number compared to, for example, the number
of cognitive or functional measures that have been devel-
oped and are routinely used in AD clinical trials [14].
Although more papers were included in our summary of
preferences work, there was no evidence of any of this
work being conducted in a clinical trial—rather all the
work was either of hypothetical scenarios being tested using
qualitative or quantitative methods in a variety of nontrial
populations such as questionnaires, surveys, and, predomi-
nantly, focus group discussions. We note that there is no
analysis of the statistical challenges in measuring patientDownloaded for Anonymous User (n/a) at NESLI The University of Ed
For personal use only. No other uses without permission. Cpreferences in the AD population. There was no clear indica-
tion from our review of the barriers to implementation of this
work into clinical trials though one could speculate that ease
of use, psychometric insufficiencies, and bias toward or fa-
miliarity with using traditional outcome measures all play
a part.4. Discussion
4.1. A need for electronic Person-Specific Outcome
Measure (ePSOM)
The current review identified a lack of PROMs being used
in AD clinical trials despite the fact that incorporating
outcome measures to reflect clinically meaningful benefits
are recommended by regulatory bodies.
4.2. PROMs and cognition
Cognitive impairment is the key diagnostic criterion in
existing definitions of AD though multiple other symp-
tomatic domains exist; for example, neuropsychiatric,
behavioral, and functional. Cognition though predomi-
nates in the conceptualization of neurodegeneration and
is therefore used as the primary outcome measures in
clinical trials to measure success. The use of cognitive
outcomes as the primary measure of success may have
been reinforced as a consequence of the first successful
pharmacological interventions showing a particular
benefit in minimizing decline in cognitive symptoms,
which has endorsed this outcome domain in all subse-
quent drug development. However, AD and other demen-
tia syndromes are experienced in a more varied manner by
the patient and caregiver with impact of the disease on a
range of cognitive, functional, behavioral, and neuropsy-
chiatric outcomes all of which will interplay and impact
on well-being. Therefore, in addition to measuring cogni-
tion, trials in an early AD and MCI population would
ideally need to incorporate sensitive measures that capture
treatment efficacy or clinically meaningful benefit as
experienced by the individual trial participant. Elsewhere,
clinically meaningful benefit has been defined as a favor-
able, statistically robust effect on how a patient feels,
functions, and/or survives [47]. It could be argued that a
PROM would accord with this definition more closely
than, for example, memory outcomes.
4.3. PROMs and biomarkers
Recently, in addition to cognitive measures, there has
been an emergence of the use of biomarker outcomes in
clinical trials, but as suggested earlier (Fig. 1), biomarker
changes are probably even less well linked to PROMs
than cognitive and functional symptoms. The emergence
of biomarker-driven decision-making leads to the patient
being communicated benefit (or lack of) via a hard to
contextualize outcome, for instance, a change of value ininburgh from ClinicalKey.com by Elsevier on January 08, 2019.
opyright ©2019. Elsevier Inc. All rights reserved.
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“negative” though may have very little direct impact on, for
example, ability to drive in a preclinical or prodromal pa-
tient. With the ePSOM program, we aim to develop and un-
derstand PROMs at multiple stages of disease, that is, in
the at-risk, MCI, and mild dementia populations and use
this information to inform the development of a psycho-
metrically robust outcome measurement platform for use
in clinical trials. We will within the program also be able
to explore the relationship between ePSOM-derived
PROMs and disease states through application of this
outcome measure in, for example, the European Prevention
of Alzheimer’s Dementia [8] or PREVENT Dementia [48]
projects where much detail is collected on biomarkers and
sensitive measures of cognitive change in preclinical and
prodromal populations (Table 1). This will allow us to
determine the degree of surrogacy between biomarkers,
cognition, and PROMs (Fig. 1). One example we could
explore would be the degree to which changes in hippo-
campal subfields (biomarker) are associated with allocen-
tric visuospatial memory (cognition) and ability to drive
(PROM/ePSOM).4.4. PROMs and preferences
Relating PROMs to other outcome measures used is a
prerequisite in the ePSOM program whereby we create
preferences methodologies that can be applied in clinical
trials. Our review has demonstrated a distinct lack of previ-
ous research that has as its goal the implementation of
PROMs or preferences in clinical trials. We argue that the
preference scales that exist outside of AD while being
generic for clinical trials do not address the complexities
and intricacies of AD pathology. In AD, there remains a
high probability that people who test positive in certain
biomarker assessments do not decline to dementia [49]. In
contrast to, for example, cancer assessments, this leads to
greater uncertainty in what is conveyed to the patient andTable 1
Barriers to implementation of PROM outcomes and preference analysis in AD cl
Current problems with PROMs in AD research
1. Psychometric properties
2. Applicability in clinical trials
3. Tradition of using cognitive and functional measures
Current problems with patient preferences in AD research
1. Measuring “benefits” using biomarkers despite poor association with
clinical condition and PROMs
2. Qualitative similarities in cognitive and functional decline in normal
aging and those due to AD pathology
3. Patient’s perception of illness
Abbreviations: AD, Alzheimer’s disease; ePSOM, electronic Person-Specific O
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For personal use only. No other uses without permission. Chow treatment decisions and trade-offs are made. Other
fields benefit from categorical outcomes like death or tumor
growth/resolution/spread. Therefore, in AD, the ability to
correlate a biomarker or cognitive outcome to a PROM is
critical but currently lacking and therefore undermining
the continued use of biomarkers and cognition as the
“benefit” to balance against the “risk” of the intervention
from a patient perspective.
A further consideration in the use of preferences in de-
mentia is the challenge of distinguishing changes between
function associated with the development and increase of
AD pathology and those associated with aging-related
changes or other clinical conditions. It would be necessary
to establish whether decline in any outcome measure in an
individual occurs as a consequence of normal aging or due
to pathological changes consistent with neurodegenerative
disease. This again is different in, for example, cancer
where the presence of illness is unambiguous and it is
possible to clearly determine what constitutes as pathology
and how tightly correlated this is to symptoms. Therefore,
because of the underlying uncertainty around the diag-
nostic accuracy of biomarkers of AD (particularly at an
earlier preclinical or prodromal stage of the disease contin-
uum) as well as the overlap in “symptoms” with normal ag-
ing and neurodegenerative disease, it is not appropriate to
fully replicate the methods used in other disease areas to
elicit patient preferences in AD. The application of our
ePSOM in deeply phenotyped cohort studies, for example,
European Prevention of Alzheimer’s Dementia will help
to address empirically the association between novel
biomarkers, sensitive cognitive measures, and specific
PROMs.5. Conclusions
To date, efficacy outcomes used in AD trials have been
uniquely cognitive or functional. However, there remains
debate about the clinical meaningfulness of these outcomes,inical trails with solutions from the ePSOM development program
ePSOM solution
We are working with regulatory bodies (EMA) and biostatistical expertise
to develop a valid and reliable PROM
The ePSOM app will have an ease of application through various stages
of development including field-testing in EPAD.
Delivery of (1) and (2) addressing those concerns leading to incorporation
of meaningful outcomes to the trial participant in clinical trials
ePSOM solution
Applying the ePSOM app to deeply phenotyped cohort studies to investigate
the association between biomarkers and cognitive outcomes and
PROMs (cross-sectionally and longitudinally)
Incorporate patient’s perception of illness measures in the ePSOM app
utcome Measure; PROM, patient-reported outcome measure.
inburgh from ClinicalKey.com by Elsevier on January 08, 2019.
opyright ©2019. Elsevier Inc. All rights reserved.
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sors, investigators, or regulators. PROMs use is conceptually
preferable and generally advocated as is how these
drive preferences for treatment (benefit versus risk), but
methodological problems have hampered their use, so there
is an expedient default back to cognitive and functional
proxy measures of brain disease.
Here, we report the first stage (literature review) and
the fundamentals of a wider research program developing
and validating an electronic person-specific outcome mea-
sure. This will be in the form of an app to capture clini-
cally meaningful treatment efficacy to be used in a
prodromal AD population. Concurrently, we are devel-
oping the biostatical approaches to assessing preferences
learning from other branches of medicine but adapting
these to the specific challenges outlined above in the
AD field. Ultimately, we will be applying the ePSOM in
cohort studies as an end point to support other outcome
domains.
So far, the use of PROMs has been limited due to time
burden in a clinical trial being a key factor. Moreover, the
psychometric properties of these measures need to be such
that regulators, investigators, and payers can agree on their
validity and reliability as outcomes in clinical trials. In the
light of these concerns, the ePSOM development program
will result in a bespoke app with a flexible multimodal
interface that will generate valid and reliable outcomes
regarding the effectiveness of an intervention to trial par-
ticipants. This will innovate the outcome measures used
in AD clinical trials to match the scientific advances in
our understanding of the disease pathology and ensure
that the interventions that come to market in the future
benefit patients in a way that they both recognize and
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1. Systematic review: As the first step of the electronic
Person Specific Outcome Measure (ePSOM) devel-
opment programme, we carried out a literature review
on patient reported outcome measures (PROMs) and
patient preferences used in clinical trials or other
research settings in the Alzheimer’s disease (AD)
population. EMBASE database was searched from
1980 until 06 Aug 2018 using OVID SP. We aimed
to identify papers referring to PROMs or patient pref-
erences in the AD and mild cognitive impairment
(MCI) population in clinical trials in order to evaluate
whether PROMs or patient preferences are currently
used in the AD population.
2. Interpretation: Currently, AD clinical trials do not
use PROMs though the need for clinically meaning-
ful outcomes is supported by regulatory bodies e.g.,
European Medicines Agency and FDA. Quality of
Life and Activities of Daily Living scales are
currently used as proxies for PROMs though there
are inconsistencies in caregiver-patient ratings
and the scales’ validities as PROMs. To assess treat-
ment preferences regarding the trade-offs in desired
benefits versus acceptable risks, no specific scales
exist in the Alzheimer’s disease population. Howev-
er, it is critical to understand how individuals make
health care decisions and include patients’ prefer-
ences for treatment options in order to reflect mean-
ingful results in clinical trials and yield better
compliance to treatment. This would mean account-
ing for the risks versus benefits analyses trial partic-
ipants or patients make for each option.
3. Future directions: The ePSOM development pro-
gramme aims to explore meaningful outcomes and
preferences that matter to patients in assessing drug
efficacy in AD. This paper outlines the framework
for a large research programme ultimately aimed to
develop an ePSOM app employing artificial intelli-
gence technologies that can be incorporated in AD
clinical trials.References
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